157 related articles for article (PubMed ID: 35056979)
1. Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy.
Cho H; Shim MK; Yang S; Song S; Moon Y; Kim J; Byun Y; Ahn CH; Kim K
Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056979
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy.
Cho H; Shim MK; Moon Y; Song S; Kim J; Choi J; Kim J; Lee Y; Park JY; Kim Y; Ahn CH; Kim MR; Yoon HY; Kim K
Pharmaceutics; 2022 Oct; 14(10):. PubMed ID: 36297566
[TBL] [Abstract][Full Text] [Related]
3. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis.
Kim J; Shim MK; Cho YJ; Jeon S; Moon Y; Choi J; Kim J; Lee J; Lee JW; Kim K
Biomaterials; 2021 Dec; 279():121189. PubMed ID: 34695659
[TBL] [Abstract][Full Text] [Related]
4. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
5. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
6. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
8. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
9. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
11. Recent Trends in
Sun IC; Yoon HY; Lim DK; Kim K
Bioconjug Chem; 2020 Apr; 31(4):1012-1024. PubMed ID: 32163277
[TBL] [Abstract][Full Text] [Related]
12. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy.
Shim MK; Moon Y; Yang S; Kim J; Cho H; Lim S; Yoon HY; Seong JK; Kim K
Biomaterials; 2020 Dec; 261():120347. PubMed ID: 32889501
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).
Zhong YJ; Shao LH; Li Y
Int J Oncol; 2013 Feb; 42(2):373-83. PubMed ID: 23291656
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrug.
Kim HY; Um SH; Sung Y; Shim MK; Yang S; Park J; Kim ES; Kim K; Kwon IC; Ryu JH
J Control Release; 2020 Dec; 328():222-236. PubMed ID: 32866592
[TBL] [Abstract][Full Text] [Related]
17. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
Abu Ajaj K; Biniossek ML; Kratz F
Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
[TBL] [Abstract][Full Text] [Related]
18. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor.
Chung SW; Choi JU; Lee BS; Byun J; Jeon OC; Kim SW; Kim IS; Kim SY; Byun Y
Biomaterials; 2016 Jul; 94():1-8. PubMed ID: 27085176
[TBL] [Abstract][Full Text] [Related]
19. Precisely albumin-hitchhiking tumor cell-activated reduction/oxidation-responsive docetaxel prodrugs for the hyperselective treatment of breast cancer.
Wei W; Luo C; Yang J; Sun B; Zhao D; Liu Y; Wang Y; Yang W; Kan Q; Sun J; He Z
J Control Release; 2018 Sep; 285():187-199. PubMed ID: 30017721
[TBL] [Abstract][Full Text] [Related]
20. Polymeric prodrug combination to exploit the therapeutic potential of antimicrobial peptides against cancer cells.
Kelly GJ; Kia AF; Hassan F; O'Grady S; Morgan MP; Creaven BS; McClean S; Harmey JH; Devocelle M
Org Biomol Chem; 2016 Oct; 14(39):9278-9286. PubMed ID: 27722734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
